Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Leukemia

Volumn 30, Issue 4, 2016, Pages 897-905

  Toma, A ^a   Kosmider, O ^b   Chevret, S ^c   Delaunay, J ^d   Stamatoullas, A ^e   Rose, C ^f   Beyne Rauzy, O ^g   Banos, A ^h   Guerci Bresler, A ⁱ   Wickenhauser, S ^j   Caillot, D ^k   Laribi, K ^l   De Renzis, B ^m   Bordessoule, D ⁿ   Gardin, C ^o   Slama, B ^p   Sanhes, L ^l   Gruson, B ^q   Cony Makhoul, P ^r   Chouffi, B ^l   Salanoubat, C ^l   Benramdane, R ^l   Legros, L ^s   Wattel, E ^t   Tertian, G ^u   Bouabdallah, K ^v   Guilhot, F ^w   Taksin, A L ^x   Cheze, S ^y   Maloum, K ^z   Nimuboma, S ^aa   Soussain, C ^ab   Isnard, F ^ac   Gyan, E ^ad   Petit, R ^c   Lejeune, J ^c   Sardnal, V ^b   Renneville, A ^ae   Preudhomme, C ^ae   Fontenay, M ^b   Fenaux, P ^c   Dreyfus, F ^b   more..

^a HENRI MONDOR HOSPITAL   (France)

^b Institut Cochin   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e CENTRE HENRI BECQUEREL   (France)

^f HÔPITAL SAINT VINCENT DE PAUL   (France)

^g CHU PURPAN   (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

^j NÎMES UNIVERSITY HOSPITAL   (France)

^k DIJON UNIVERSITY HOSPITAL   (France)

^l CENTRE HOSPITALIER   (France)

^m UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁿ LIMOGES UNIVERSITY HOSPITAL   (France)

^o AVICENNE HOSPITAL   (France)

^p CENTRE HOSPITALIER D AVIGNON   (France)

^q AMIENS UNIVERSITY HOSPITAL   (France)

^r Centre hospitalier Annecy I   (France)

^s UNIVERSITY HOSPITAL OF NICE   (France)

^t EDOUARD HERRIOT HOSPITAL   (France)

^u BICÊTRE HOSPITAL   (France)

^v BORDEAUX UNIVERSITY HOSPITAL   (France)

^w University of Poitiers   (France)

^x CENTRE HOSPITALIER DE VERSAILLES   (France)

^y CAEN UNIVERSITY HOSPITAL   (France)

^z PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^aa RENNES UNIVERSITY HOSPITAL   (France)

^ab CENTRE RENÉ HUGUENIN   (France)

^ac HÔPITAL SAINT ANTOINE   (France)

^ad UNIVERSITY HOSPITAL OF TOURS   (France)

^ae LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; AZACITIDINE; DEFERASIROX; ERYTHROPOIETIN; LENALIDOMIDE; RECOMBINANT ERYTHROPOIETIN; ANGIOGENESIS INHIBITOR; THALIDOMIDE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; CONTROLLED STUDY; CRBN GENE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; GENE; GENETIC POLYMORPHISM; GOUT; HEART FAILURE; HUMAN; INTENTION TO TREAT ANALYSIS; INTESTINE OBSTRUCTION; KIDNEY FAILURE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NON DEL5Q MYELODYSPLASTIC SYNDROME; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD TRANSFUSION; CANCER STAGING; CHROMOSOME 5; CHROMOSOME DELETION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; FOLLOW UP; GENETICS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PROGNOSIS; RISK FACTOR;

AGED; ANEMIA; ANGIOGENESIS INHIBITORS; BLOOD TRANSFUSION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; THALIDOMIDE;

EID: 84954348593     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.296     Document Type: Article

References (35)

1. Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet 2014; 383: 2239-2252
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088
3. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465
4. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colonystimulating factor plus erythropoietin: results from a randomized phase II study and long-Term follow-up of 71 patients. Blood 1998; 92: 68-75
5. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 104: 321-327
6. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111: 574-582
7. Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26: 3607-3613
8. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114: 2393-2400
9. Sekeres MA, Steensma DP. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. Blood 2009; 114: 2575-2580
10. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-Alpha. J Immunol 1999; 163: 380-386
11. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-557
12. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465
13. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, et al Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86-93
14. Sibon D, Cannas G, Baracco F, Prebet T, Vey N, Banos A, et al. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br J Haematol 2012; 156: 619-625
15. Komrokji RS, Garcia-Manero G, Ades L, Laadem A, Vo B, Prebet T, et al. An openlabel, phase 2, dose-finding study of sotatercept (ACE-011) in patients with low or intermediate-1 (Int-1)-risk myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML) and anemia requiring transfusion. ASH Annual Meeting Abstracts, 2014; abstract 3251
16. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951
17. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943-2964
18. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425
19. Sardnal V, Rouquette A, Kaltenbach S, Bally C, Chesnais V, Leschi C, et al. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia 2013; 27: 1610-1613
20. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985; 41: 361-372
21. Fenaux P, Haase D, Sanz GF, Santini V, Buske C ESMO Guidelines Working Group Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: iii57-iii69
22. Narla A, Dutt S, McAuley JR, Al-Shahrour F, Hurst S, McConkey M, et al. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood 2011; 118: 2296-2304
23. Fink EC, Krönke J, Hurst SN, Udeshi ND, Svinkina T, Schneider RK, et al. Lenalidomide induces ubiquitination and degradation of CSNK1A1 in MDS with Del(5q). ASH Annual Meeting Abstracts, 2014; 124, abstract 4
24. List A, Estes M, Gao G, Janokowska A, Maciejewski J. Large CD45 protein tyrosine phosphatase (PTP) isoforms predominate in myelodysplastic erythroid precursors and attenuate the erythropoietin (EPO): STAT5 signal. ASH Annual Meeting Abstracts, 2006; 108, abstract 2650
25. McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, et al. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One 2014; 9: e114249
26. Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, et al. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood 2012; 120: 3419-3424
27. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974-12979
28. Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008; 87: 345-352
29. Thepot S, Abdelali RB, Chevret S, Renneville A, Rauzy OB, Prebet T, et al. Prognostic factors of response and survival to azacitidine (AZA) +/- EPO in RBC transfusion dependent (TD) IPSS low and Int-1 (LR) MDS resistant to EPO, with particular emphasis of genetic lesions: a study by the GFM. ASH Annual Meeting Abstracts, 2013; abstract 658
30. Tobiasson M, Dybedahl I, Holm MS, Karimi M, Brandefors L, Garelius H, et al. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low-And Int-1-risk MDS: results from the nordic NMDSG08A phase II trial. Blood Cancer J 2014; 4: e189
31. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 2505-2511
32. Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010; 28: 5166-5173
33. Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, et al. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer 2012; 118: 2138-2147
34. Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, et al. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res 2015; 21: 985-994
35. Platzbecker U, Germing U, Giagounidis A, Goetze K, Kiewe P, Mayer K, et al. ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from a phase 2 study. ASH Annual Meeting Abstracts, 2014; abstract 411